NDA 22051, held by Haleon US Holdings. Fluticasone Furoate.
As of Nov 16, 2026, NDA 22051 (Flonase Sensimist Allergy Relief), held by Haleon US Holdings, was first approved by FDA on Apr 27, 2007, with 13 approved supplements and 0 published complete response letters.
Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies:
| Aug 2, 2016 | Supplement 13Efficacy (new indication or use) · Standard review | Approved | |
| Aug 21, 2012 | Supplement 8Efficacy (new indication or use) · Standard review | Approved | None posted |
| Apr 27, 2007 | Original applicationNew active ingredient · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Flonase Sensimist Allergy Relief0.0275MG/SPRAY · spray, metered;nasal | Fluticasone Furoate | OTCReference drug |
| Dec 19, 2025 | Supplement 27Labeling · Standard review | Approved | |
| Sep 15, 2025 | Supplement 25Labeling · Standard review | Approved | |
| Jan 10, 2025 | Supplement 24Labeling · Standard review | Approved | |
| Oct 24, 2024 | Supplement 23Labeling · Standard review | Approved | |
| Nov 15, 2023 | Supplement 21Labeling · Standard review | Approved | |
| Aug 23, 2017 | Supplement 17Labeling · Standard review | Approved | |
| Apr 5, 2017 | Supplement 14Labeling · Standard review | Approved | |
| Aug 2, 2016 | Supplement 13Efficacy (new indication or use) · Standard review | Approved | |
| May 21, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 21, 2012 | Supplement 8Efficacy (new indication or use) · Standard review | Approved | None posted |
| Oct 13, 2011 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 1, 2011 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 28, 2009 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 27, 2007 | Original applicationNew active ingredient · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters